A dye composition dissolvable within a liquid crystal host device (including: polymer dispersed liquid crystal, polymer network liquid crystal, polymer stabilized liquid crystal, liquid crystal displays and similar devices), comprising eutectic mixtures of dichroic metallomesogen molecules. The aforesaid metallomesogen molecules comprise chromophore groups synthesized by physical and chemical mixing methods.

Disclosed is a fluorescent compound for the detection of isocyanate substances, a preparation method therefor and use thereof as a test-paper-type detection probe. The fluorescent compound is 2,4-di(((4′-(diphenylamino)-[1,1′-biphenyl]-4-yl)imino)methyl)phenol. The fluorescent compound is prepared by means of a one-step method. The fluorescent compound has simple and convenient preparation with high yield, and is capable of making a rapid and specific response to isocyanate substances. Moreover, the fluorescence intensity of the fluorescent compound will enhance with the increase of the isocyanate concentration. The fluorescent compound can be made into a portable test-paper-type probe for the detection of isocyanate substances in air, and can achieve the visual detection of volatile isocyanate gases. The probe has an aggregation-induced emission effect, and thus it has higher fluorescence quantum yield when using a test-paper-type probe for detection.

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.

Disclosed is a fluorescent compound for the detection of isocyanate substances, a preparation method therefor and use thereof as a test-paper-type detection probe. The fluorescent compound is 2,4-di(((4′-(diphenylamino)-[1,1′-biphenyl]-4-yl)imino)methyl)phenol. The fluorescent compound is prepared by means of a one-step method. The fluorescent compound has simple and convenient preparation with high yield, and is capable of making a rapid and specific response to isocyanate substances. Moreover, the fluorescence intensity of the fluorescent compound will enhance with the increase of the isocyanate concentration. The fluorescent compound can be made into a portable test-paper-type probe for the detection of isocyanate substances in air, and can achieve the visual detection of volatile isocyanate gases. The probe has an aggregation-induced emission effect, and thus it has higher fluorescence quantum yield when using a test-paper-type probe for detection.

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.

A dye composition dissolvable within a liquid crystal host device (including: polymer dispersed liquid crystal, polymer network liquid crystal, polymer stabilized liquid crystal, liquid crystal displays and similar devices), comprising eutectic mixtures of dichroic metallomesogen molecules. The aforesaid metallomesogen molecules comprise chromophore groups synthesized by physical and chemical mixing methods.

Fluorescent chromophores nicknamed BOPHY are provided. The chromophores may be readily synthesized in two steps from readily available reagents via the coupling of a pyrrole aldehyde or ketone with hydrazine, followed by reaction with BF.sub.3. The resultant symmetric and dimeric tetracycle is comprised of two BF.sub.2 units in six-member chelate rings, appended by pyrrole units on the periphery. The quantum yield of fluorescence for the unmodified compound and the tetramethyl variant are near unity, with values 95 and 92% respectively in CH.sub.2Cl.sub.2.

Electrowetting element including a compound comprising a plurality of colorant moieties and a linker. The plurality of colorant moieties includes a first colorant moiety having a first net dipole and a second colorant moiety having a second net dipole. The plurality of colorant moieties are linked by and disposed around the linker so that the first net dipole and the second net dipole at least partially cancel each other.

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.